Keyword: Yescarta (axicabtagene ciloleucel)
Gilead will locate the European manufacturing site for its CAR-T therapy Yescarta at a Netherlands airport to ensure quick turnaround for its patients.
Gilead may have some exciting prospects ahead, but for now, its cash-cow hepatitis C business is a big drag. The good news? It's a 'trough year.'
If the competition between Novartis and Gilead in relapsed large B-cell lymphoma comes down to price, it will be a close race.
CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's requested add-on payment.
A host of challenges that drove Gilead's revenues down 14% last year didn’t stop its board from boosting the CEO’s pay package to $15.4 million.
Never underestimate the power of positivity, which triumphed in the latest round of voting in FiercePharma’s drug-naming shootout.
Drug spending in developed countries will fall this year, IQVIA says. The curbing effect? Rebates that more than offset pharma's price-hike haul.
Gilead's executive v.p. of worldwide commercial operations is unexpectedly retiring, at a time when the company is facing challenges across its infectious-disease and oncology portfolios.
A new analysis suggests Novartis could make a decent profit on Kymriah if the cost was just one-third its current price of $475,000.